Subcutaneous delivery of an antibody against SARS-CoV-2 from a supramolecular hydrogel depot.

ABSTRACT: Prolonged maintenance of therapeutically-relevant levels of broadly neutralizing antibodies (bnAbs) is necessary to enable passive immunization against infectious disease. Unfortunately, protection only lasts for as long as these bnAbs remain present at a sufficiently high concentration in the body. Poor pharmacokinetics and burdensome administration are two challenges that need to be addressed in order to make pre- and post-exposure prophylaxis with bnAbs feasible and effective. In this work, we develop a supramolecular hydrogel as an injectable, subcutaneous depot to encapsulate and deliver antibody drug cargo. This polymer-nanoparticle (PNP) hydrogel exhibits shear-thinning and self-healing properties that are required for an injectable drug delivery vehicle. In vitro drug releas

SUBMITTER: Kasse CM 

PROVIDER: S-EPMC10012178 | biostudies-literature | 2023 Mar

REPOSITORIES: biostudies-literature